CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 304 enrolled
Drug / intervention
diclofenac diethylamine, DDEA 2.32% gel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01967550
NCT01967550Phase 3Completed

A 4-week, Randomized, Double-blind, Multi-center, Vehicle-controlled, Parallel Group Study to Assess the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel for the Relief of Signs and Symptoms in Patients With Knee Osteoarthritis

Novartis·interventional·Posted Oct 23, 2013·Updated Jun 3, 2015

In Brief

A Phase 3 clinical trial evaluating diclofenac diethylamine, DDEA 2.32% gel and Placebo for Osteoarthritis, Knee. Completed, enrolled 304 participants across 5 sites.

Detailed Summary

This study will evaluate the efficacy and safety of diclofenac DDEA 2.32 % in patient suffering from knee osteoarthritis (OA).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 23, 2013
Enrollment StartOct 1, 2013
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.7 years ago

Interventions

diclofenac diethylamine, DDEA 2.32% geldrug

Placebodrug